期刊论文详细信息
American Journal of Immunology
β1,3-GLUCAN ANTICANCER EFFICACIES AND SYNERGIES: A REVIEW | Science Publications
Angove Michael1  Story Jenny1  Vetvicka Vaclav1 
关键词: Cancer;    Chemotherapy;    Glucan;    Immunomodulators;    Monoclonal Antibodies;   
DOI  :  10.3844/ajisp.2014.131.143
学科分类:过敏症与临床免疫学
来源: Science Publications
PDF
【 摘 要 】

β1,3-glucans from fungi, cereals, seaweeds and bacteria have been shown to possess favourable biological and anti-carcinogenic activities including upregulation of phagocytosis, cytokine production enhancement, superoxide and nitrite production; antibody secretion and stimulation of signalling pathways associated with proto-oncogene expression. However, human dietary supplements containing β1,3-glucans vary in efficacy due to glucan source, the lifecycle stage of the source at extraction, extraction methods, purity, concentration and combination with other immunomodulators. A review of efficacy of some commercially available β1,3-glucan products is presented. Three apparently efficacious products in which β1,3-glucan was the only immunomodulator were identified: Glucan #300®, Maitake Gold 404® (diluted Yukiguni Maitake MD Fraction®) and Betamune®. A trial of Maitake Gold 404® produced evidence of standardisation problems. It is recommended that Yukiguni Maitake MD Fraction® (a more standardised alternative), Glucan #300® and Betamune® be comparatively trialled at optimal doses across immunological measures and tumor reduction. β1,3-glucans have been shown to be synergistic with conventional cancer therapies and monoclonal antibodies, as well as immunomodulators including vitamin C, transresveratrol, humic acids and Ashwagandha (Withania somnifera). Trialled commercially available products containing immunomodulator combinations have been shown to be inefficacious, apart from RVB300®, a β1,3-glucan/transresveratrol/vitamin C combination. The efficacies of various combinations of β1,3-glucans with other immunomodulators and the details of specific β1,3-glucan/monoclonal antibody synergies in treating particular cancer cell lines, require systematic elucidation.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201912010159947ZK.pdf 155KB PDF download
  文献评价指标  
  下载次数:10次 浏览次数:27次